TY  - JOUR
AU  - Steinbügl, Mona
AU  - Nemes, Karolina
AU  - Johann, Pascal
AU  - Kröncke, Thomas
AU  - Tüchert, Stefanie
AU  - da Costa, Maria Joao Gil
AU  - Ebinger, Martin
AU  - Schüller, Ulrich
AU  - Sehested, Astrid
AU  - Hauser, Peter
AU  - Reinhard, Harald
AU  - Sumerauer, David
AU  - Hettmer, Simone
AU  - Jakob, Marcus
AU  - Hasselblatt, Martin
AU  - Siebert, Reiner
AU  - Witt, Olaf
AU  - Gerss, Joachim
AU  - Kerl, Kornelius
AU  - Frühwald, Michael C
TI  - Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors.
JO  - Pediatric blood & cancer
VL  - 68
IS  - 12
SN  - 1545-5017
CY  - New York, NY
PB  - Wiley
M1  - DKFZ-2021-01755
SP  - e29267
PY  - 2021
N1  - 2021 Dec;68(12):e29267
AB  - Refined therapy has helped to improve survival rates in rhabdoid tumors (RT). Prognosis for patients with chemoresistant, recurrent, or progressive RT remains dismal. Although decitabine, an epigenetically active agent, has mainly been evaluated in the management of hematologic malignancies in adults, safety in children has also been demonstrated repeatedly.A retrospective series of patients who received decitabine upon relapse or progression following therapy according to the EU-RHAB regimen is presented. Due to the retrospective nature of analyses, response was defined as measurable regression of at least one lesion on imaging. 850k methylation profiling was done whenever tumor tissue was available.A total of 22 patients with RT of any anatomical localization were included. Most patients (19/22) presented with metastases. All received low-dose decitabine with or preceding conventional chemotherapy. Patients received a median of two (1-6) courses of decitabine; 27.3
KW  - ATRT (Other)
KW  - decitabine (Other)
KW  - malignant rhabdoid tumor (Other)
KW  - relapsed and refractory rhabdoid tumors (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34347371
DO  - DOI:10.1002/pbc.29267
UR  - https://inrepo02.dkfz.de/record/170092
ER  -